yeah agree. $5.5m not a lot, the accent trial will burn through a lot now, once you expand a trial to other countries costs ramp up quickly with a CRO running it. these CROs ain't charities and I've heard stories of them charging like wounded bulls..
//and a USA trial won't be cheap, they typically charge a lot over there, more than Europe.
//it is possible to get an IND but choose not to do a trial in US, I've heard anecdotally of companies just getting the IND for purposes of kudos having an FDA tick for your drug's profile, but then run a trial elsewhere. what I don't understand is why didn't they bolt on the folfirox /AMP combination onto Accent as a kind of parallel study, might have been more efficient and cost-effective?
yeah agree. $5.5m not a lot, the accent trial will burn through...
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.2¢ |
Change
0.001(1.64%) |
Mkt cap ! $16.56M | |||
| Open | High | Low | Value | Volume |
| 6.1¢ | 6.2¢ | 6.1¢ | $9.156K | 150.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.2¢ | 169665 | 3 |
View Market Depth
| Last trade - 13.04pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.1¢ |
Change
0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 6.1¢ | 6.2¢ | 6.1¢ | 30506 | ||
| Last updated 12.11pm 16/05/2024 ? | |||||
| ATX (ASX) Chart |